P 7435

Drug Profile

P 7435

Alternative Names: P-7435; P7435-DGAT1

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Piramal Life Sciences
  • Developer Piramal Enterprises
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetes mellitus; Lipid metabolism disorders

Highest Development Phases

  • Phase I Diabetes mellitus; Lipid metabolism disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in India (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lipid-metabolism-disorders(In volunteers) in India (PO, Tablet)
  • 24 Nov 2014 Piramal Enterprises completes a phase I trial in healthy, overweight or obese subjects in USA (NCT01910571)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top